FDA approves sNDA for eltrombopag in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy. Read more

Results show that the company's European biosimilar epoetin, Retacrit (epoetin zeta) was effective and well tolerated in the management of chemotherapy-induced anemia in patients with solid tumours, lymphoma and myeloma. Read more